International Stem Cell Corp. (ISCO.OB) to Conduct Experiments to Get Clear View of Age-Related Macular Degeneration
Biotechnology company International Stem Cell Corporation today announced that its Research and Therapeutic Development Group will team up with scientists from the University of California, Irvine to conduct a second phase of preclinical experiments on retinal pigment epithelium (RPE), (in layman’s terms, the colored cell layer of the retina), derived from parthenogenetic stem cells. RPE is an integral part of proper eye function. The loss of function contributes to a variety of disabling eye conditions, including age-related macular degeneration (AMD), the leading cause of vision loss in seniors. ISCO’s preclinical research will allow scientists to test the restoration ability of…